← Back to Search

GLP-1 Receptor Agonist

A Study of LY3437943 in Participants With Type 2 Diabetes

Wilmington, NC
Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose: week 0, 1, 4, 12, 24, 30; postdose: week 2, 8, 16, 20, 36

Summary

This trial will evaluate a new drug for type 2 diabetes in people who have not been able to control their diabetes with diet and exercise or with metformin. The trial will last 43 weeks.

See full description
Eligible Conditions
  • Type 2 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose: week 0, 1, 4, 12, 24, 30; postdose: week 2, 8, 16, 20, 36
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose: week 0, 1, 4, 12, 24, 30; postdose: week 2, 8, 16, 20, 36 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change From Baseline in Hemoglobin A1c (HbA1c)
Secondary study objectives
Change From Baseline in Body Weight
Change From Baseline in Fasting Blood Glucose (FBG)
Change From Baseline in HbA1c
+3 more

Side effects data

From 2022 Phase 2 trial • 281 Patients • NCT04867785
27%
Nausea
19%
Diarrhoea
19%
Decreased appetite
12%
Constipation
12%
Headache
12%
Lipase increased
8%
Sinusitis
8%
Dyspepsia
8%
Vomiting
8%
Weight decreased
6%
Vaginal haemorrhage
4%
Pancreatitis acute
4%
Abdominal pain
4%
Covid-19
4%
Upper respiratory tract infection
4%
Dizziness
4%
Eructation
4%
Atrial fibrillation
4%
Fatigue
4%
Urinary tract infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
8 mg LY3437943 (2 mg)
12 mg LY3437943 (2 mg)
Placebo
1.5 Milligram (mg) Dulaglutide
0.5 mg LY3437943
4 mg LY3437943 (2 mg)
4 mg LY3437943 (4 mg)
8 mg LY3437943 (4 mg)

Trial Design

8Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: 8 mg LY3437943 (4 mg)Experimental Treatment1 Intervention
Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as a SC injection QW.
Group II: 8 mg LY3437943 (2 mg)Experimental Treatment1 Intervention
Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.
Group III: 4 mg LY3437943 (4 mg)Experimental Treatment1 Intervention
Participants received 4 mg LY3437943 administered as SC injection QW.
Group IV: 4 mg LY3437943 (2 mg)Experimental Treatment1 Intervention
Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.
Group V: 12 mg LY3437943 (2 mg)Experimental Treatment1 Intervention
Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as a SC injection QW.
Group VI: 0.5 milligrams (mg) LY3437943Experimental Treatment1 Intervention
Participants received 0.5 mg LY3437943 administered as SC (subcutaneous) injection once weekly (QW).
Group VII: 1.5 mg DulaglutideActive Control1 Intervention
Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.
Group VIII: PlaceboPlacebo Group1 Intervention
Participants received placebo administered as SC injection QW.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3437943
2022
Completed Phase 2
~1090

Find a Location

Closest Location:PMG Research of Wilmington· Wilmington, NC

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,686 Previous Clinical Trials
3,466,752 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,394 Previous Clinical Trials
429,152 Total Patients Enrolled
~59 spots leftby Feb 2026